Investors are eagerly awaiting interim data on Dendreon's Provenge, hoping that the October report will indicate that the developer's cancer therapy can demonstrate that it is on track to win over a hesitant FDA. Forbes notes that positive data will drive a BLA, which would speed approval. Final data won't arrive, though, until the latter half of 2009. Story